$1.06 Billion is the total value of Paradigm Biocapital Advisors LP's 25 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 52.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BIIB | Buy | BIOGEN INC | $97,197,342 | +47.0% | 349,593 | +46.4% | 9.21% | +18.7% |
| INCY | Buy | INCYTE CORP | $91,183,854 | +33.1% | 1,261,711 | +47.9% | 8.64% | +7.5% |
| LEGN | Buy | LEGEND BIOTECH CORPsponsored ads | $72,827,823 | +38.3% | 1,510,324 | +43.2% | 6.90% | +11.7% |
| ARGX | Buy | ARGENX SEsponsored adr | $67,501,064 | +99.0% | 181,172 | +102.3% | 6.40% | +60.6% |
| SGEN | Sell | SEAGEN INC | $57,090,263 | +55.2% | 281,969 | -1.5% | 5.41% | +25.3% |
| IMCR | Buy | IMMUNOCORE HLDGS PLCads | $55,682,097 | +13.7% | 1,126,256 | +31.3% | 5.28% | -8.2% |
| Buy | ARCELLX INC | $54,157,171 | +98.2% | 1,757,779 | +99.3% | 5.13% | +60.0% | |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $53,060,157 | +3.7% | 2,085,698 | +19.1% | 5.03% | -16.2% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $51,932,243 | -9.6% | 1,396,779 | +10.2% | 4.92% | -27.0% |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $48,037,693 | -3.4% | 2,274,512 | +16.4% | 4.55% | -22.0% |
| UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $47,455,332 | +14.6% | 211,892 | +42.3% | 4.50% | -7.5% |
| KROS | New | KEROS THERAPEUTICS INC | $39,743,110 | – | 930,752 | +100.0% | 3.77% | – |
| BGNE | New | BEIGENE LTDsponsored adr | $39,660,106 | – | 184,012 | +100.0% | 3.76% | – |
| CERE | New | CEREVEL THERAPEUTICS HLDNG I | $38,906,904 | – | 1,595,199 | +100.0% | 3.69% | – |
| BCYC | Buy | BICYCLE THERAPEUTICS PLCsponsored ads | $38,642,932 | +5.9% | 1,816,781 | +47.3% | 3.66% | -14.5% |
| ASND | Sell | ASCENDIS PHARMA A/Ssponsored adr | $37,619,853 | -12.7% | 350,866 | -0.6% | 3.56% | -29.5% |
| VOR | Buy | VOR BIOPHARMA INC | $34,851,635 | -18.7% | 6,477,999 | +0.5% | 3.30% | -34.3% |
| ZLAB | Buy | ZAI LAB LTDadr | $25,961,359 | +64.1% | 780,558 | +51.5% | 2.46% | +32.5% |
| XENE | New | XENON PHARMACEUTICALS INC | $23,301,724 | – | 651,068 | +100.0% | 2.21% | – |
| VRNA | New | VERONA PHARMA PLCsponsored ads | $19,324,209 | – | 962,361 | +100.0% | 1.83% | – |
| CRNX | Buy | CRINETICS PHARMACEUTICALS IN | $18,208,539 | +11.8% | 1,133,782 | +27.4% | 1.73% | -9.7% |
| ALPN | ALPINE IMMUNE SCIENCES INC | $17,892,134 | +5.0% | 2,317,634 | 0.0% | 1.70% | -15.2% | |
| New | THESEUS PHARMACEUTICALS INC | $13,367,304 | – | 1,505,327 | +100.0% | 1.27% | – | |
| OLMA | New | OLEMA PHARMACEUTICALS INC | $8,266,848 | – | 2,382,377 | +100.0% | 0.78% | – |
| PSTX | Sell | POSEIDA THERAPEUTICS INC | $3,303,023 | -74.4% | 1,072,410 | -56.0% | 0.31% | -79.3% |
| PRTA | Exit | PROTHENA CORP PLC | $0 | – | -75,000 | -100.0% | -0.53% | – |
| ARVN | Exit | ARVINAS INC | $0 | – | -599,599 | -100.0% | -2.41% | – |
| KRTX | Exit | KARUNA THERAPEUTICS INC | $0 | – | -106,210 | -100.0% | -2.45% | – |
| AKRO | Exit | AKERO THERAPEUTICS INC | $0 | – | -604,544 | -100.0% | -3.89% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PUB L | $0 | – | -477,585 | -100.0% | -6.38% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LEGEND BIOTECH CORP | 8 | Q3 2023 | 10.7% |
| MIRATI THERAPEUTICS INC | 8 | Q3 2023 | 10.9% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 6.8% |
| IMMUNOCORE HLDGS PLC | 8 | Q3 2023 | 5.9% |
| SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 5.8% |
| VOR BIOPHARMA INC | 8 | Q3 2023 | 5.0% |
| INCYTE CORP | 7 | Q3 2023 | 8.6% |
| ARGENX SE | 7 | Q3 2023 | 8.7% |
| UNITED THERAPEUTICS CORP DEL | 7 | Q3 2023 | 7.7% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 2.1% |
View Paradigm Biocapital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Paradigm Biocapital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.